Niels Reinmuth, MD, PhD

Articles

International Dialogue on Which Biomarkers to Prioritize in NSCLC Testing

December 1st 2025

Experts underscore that comprehensive biomarker testing is now essential not just for stage IV non-small cell lung cancer (NSCLC), but also for earlier stages, starting from stage 1b. This is driven by the approval of adjuvant targeted therapies and neoadjuvant regimens, making molecular profiling critical for curative-intent treatment planning.

Why Fast Biomarker Results are Critical for NSCLC Patients

December 1st 2025

Experts discuss the critical importance of turnaround time for comprehensive biomarker testing in NSCLC. They compare systems, with one center performing in-house NGS testing and reporting key results like EGFR and ALK via rapid FISH/PCR in 3-5 days, allowing for immediate treatment decisions without waiting for the full NGS report.

Implementing Comprehensive Genomic Testing in NSCLC Care

November 24th 2025

Experts address the critical practice of comprehensive biomarker testing for non-small cell lung cancer (NSCLC), highlighting both its necessity and the challenges in implementation. While biomarker testing is mandatory from diagnosis per guidelines, real-world barriers like insufficient tissue from biopsies often prevent complete profiling.

Global Perspectives on Lung Cancer: Targeted Therapy and Better Outcomes

November 24th 2025

Experts discuss the transformative impact of targeted therapies on outcomes in non-small cell lung cancer (NSCLC). They highlight that before these treatments, survival for stage IV patients was often measured in months. Now, the identification of driver mutations and the use of matched oral targeted therapies have fundamentally changed the disease trajectory.

Dr. Reinmuth on the Rationale for Examining PROs With Tepotinib in METex14-Altered NSCLC

September 27th 2021

Niels Reinmuth, MD, PhD, discusses the rationale for a health utility analysis of tepotinib in patients with MET exon 14 skipping mutation–positive non–small cell lung cancer.

Dr. Reimuth Discusses Studies Looking at Resistance to EGFR TKIs in NSCLC

April 25th 2019

Niels Reinmuth, MD, PhD, leader of the Thoracic Oncology Department, Asklepios Lung Clinic, discusses ongoing studies looking at resistance to EGFR TKIs in patients with EGFR-positive non–small cell lung cancer.

Dr. Reinmuth on Findings from the MYSTIC Study

April 13th 2019

Niels Reinmuth, MD, PhD, discusses the results of the MYSTIC study, which evaluated first-line durvalumab plus tremelimumab versus platinum-based chemotherapy in patients with metastatic non–small cell lung cancer.